Hepatitis News

A Smart + Strong Site

Subscribe to:
• Hepatitis E-newsletter

Join Us:

HOME

NEWS

News Hep Exclusives Hep TV

Conference Coverage Hep In Print

ABOUT HEPATITIS

Introduction PAP and Co-Pay Programs Clinical Trials

Hepatitis A Hepatitis B Hepatitis C

HEPATITIS A

Transmission Symptoms Diagnosis

Treatment Prevention

HEPATITIS B

Transmission Acute & Chronic Infection Laboratory Tests PAP and Co-Pay Programs

Symptoms Treatment Prevention

HEPATITIS C

Transmission HCV/HIV Coinfection Symptoms

Diagnosis Starting Treatment Approved Treatments

PAP and Co-Pay Programs Curing Hep C Prevention

COMMUNITY

Forums Services Directory Calendar

Blogs Hep TV Bookstore

Share Your Story Take a Poll Widgets

ABOUT US

Our Mission Our Staff

Advertise Contact Us

Back to home » Hepatitis News

May 20, 2013

FDA Gives Hep C Drug Simeprevir Priority Review
The FDA has given Janssen Research & Development priority review status for its investigational hepatitis C therapy simeprevir.

May 17, 2013

Hepatitis Testing Day 2013
May 19 is the awareness day.

May 16, 2013

N.Y. Hospitals Warn Thousands About Possible Hep Exposure
Two hospitals in upstate New York are now alerting more than 2,000 patients about their potential exposure to hepatitis and other blood-borne infections.

May 15, 2013

People With HIV, Hep May Need Permission to Marry in Bahrain
Current law already mandates engaged couples to get tested.

May 14, 2013

Sharecare Ranks Top 10 Social Healthmakers in Hepatitis C
Among those ranked were HepMag.com bloggers Lucinda K. Porter (No. 1), Margaret Dudley (No. 3), Karen Hoyt (No. 7), Connie Welch (No. 9) and Tim Horn (No. 10).

May 13, 2013

Sofosbuvir and Ledipasvir Boast High Cure Rates for Hep C
Following promising results from a Phase II trial of sofosbuvir and ledipasvir, a Phase III trial will begin of a fixed dose of the drugs to treat hepatitis C.

Test Can Easily ID Broadly Neutralizing Antibodies Against HIV
NIH-sponsored scientists have developed a powerful new assay that can screen blood for broadly neutralizing antibodies against HIV.

May 10, 2013

New 'Accountable Care' Approach Aims to Cut Medical Costs
The idea is to provide less care, but not worse care.

May 09, 2013

Advocates Say U.S. Helps Counter Hepatitis B Discrimination
Advocates are encouraged by recent federal changes regarding health professionals and students who have the hepatitis B virus.

May 08, 2013

HIV, Hep Concerns for Colonoscopy Patients in Georgia
Staff discovered that cleaning practices for endoscopy equipment were not followed completely.

May 07, 2013

Victrelis, Incivek Yield Low Hep C Cures Among Cirrhosis
Victrelis or Incivek-based triple therapy for hepatitis C virus resulted in low cure rates and high rates of serious side effects among those with cirrhosis.

National Hepatitis Awareness Month 2013
In observance of National Hepatitis Awareness Month—recognized each May—health advocates and professionals are working to decrease the burden of chronic viral hepatitis through awareness and encouraging people to get tested.

Half Who Test Positive for Hep C Fail to Confirm Result
According to the CDC, just half of Americans who test positive for hepatitis C ever receive necessary follow-up testing to confirm a chronic infection.

May 06, 2013

Post-Liver Transplant Hep C Responds to Triple Therapy
Treating hepatitis C post-liver transplant yields moderately good results with Victrelis (boceprevir) or Incivek (telaprevir)-based triple therapy.

May 03, 2013

Faldaprevir Cures 80% of Hep C in First-time Treatment
Faldaprevir with pegylated interferon and ribavirin cured about 80 percent of treatment-naive people with genotype 1 of hepatitis C in a Phase III trial.

May 02, 2013

Combo of 2 HIV Drugs Can Control Hep B
The HIV antiretrovirals Viread (tenofovir) and Emtriva (emtricitabine), can suppress hepatitis B in three-quarters of those with “immune-tolerant” infection.

California Psychiatric Hospital Warns Patrons of Hep A Risk
The San Diego County Psychiatric Hospital is giving out free vaccines to a number of patients, employees and visitors who may have been exposed to hepatitis A.

May 01, 2013

Sofosbuvir and Ribavirin Cure 90% of Most Types of Hep C
A Phase III trial sofosbuvir and ribavirin cured 90 percent of those with genotypes 1, 4, 5 and 6 of hepatitis C.

HIV, Hep Confirmed in Initial Tests of Oklahoma Dental Patients
Thousands more former patients need to be tested.

Archives

May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
January 2008